Q1 Results Lower Year on Year, as Expected; Comprehensive Action Plan Underway to Address Market Challenges

Why It Matters

The results highlight mounting pressure on the global hygiene market, while Ontex’s cost‑cutting and pricing actions aim to restore profitability and lower leverage, a key signal for investors and competitors alike.

Key Takeaways

• Revenue fell 4% YoY to €426 m (~$469 m).
• Adjusted EBITDA margin dropped to 9.1%, down 2.2 pp.
• Net financial debt cut 5% to €550 m (~$605 m).
• Adult care volumes up 2%; baby care down 11% YoY.
• Strategic review targets 15% SG&A headcount cut and capacity right‑sizing.

Pulse Analysis

Ontex operates in a highly competitive hygiene sector where demand for diapers and feminine products is increasingly sensitive to macro‑economic shocks and energy price volatility. The company’s modest adult‑care growth reflects a shift toward higher‑margin, retail‑driven segments, while the sharp 11% drop in baby‑care volumes underscores lingering softness in European retail channels. By maintaining a diversified product mix across adult, baby, and feminine care, Ontex can leverage cross‑segment pricing power, but it must navigate cost inflation from oil‑linked raw materials.

Financially, the quarter revealed a 4% revenue contraction and a 24% YoY decline in adjusted EBITDA, pushing the margin to 9.1%. The dip is largely volume‑driven, yet the company’s disciplined cost‑management helped keep operating expenses in check, trimming net debt by €27 million (≈$30 million). Pricing actions have partially offset higher input costs, but the margin squeeze signals that further efficiency gains are essential. The reduction in leverage to 3.36×, while modest, improves balance‑sheet resilience and supports the outlook for positive free cash flow later in 2026.

The ongoing strategic review is the centerpiece of Ontex’s turnaround plan. External advisors have identified opportunities to cut SG&A headcount by roughly 15% and to right‑size production capacity, including exiting baby‑diaper manufacturing in Australia. An estimated €10 million (≈$11 million) cash outlay this year will fund these initiatives, with the expectation that streamlined operations and improved working‑capital management will drive the targeted 10% EBITDA uplift. Investors will watch the Q2 results closely for evidence that the cost‑optimization roadmap translates into sustainable profitability and a stronger leverage profile.